Ziconotide vs Dermorphin
Comprehensive side-by-side comparison of mechanisms, dosing, side effects, and research
Also: Prialt, SNX-111
Ziconotide is a real, FDA-approved painkiller pulled from the venom of a marine cone snail. It is not an opioid, and unlike morphine, people do not build tolerance to it over time. The catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning.
Also: Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2, Frog juice
Dermorphin is a seven-amino-acid opioid peptide (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) first found in the skin of South American Phyllomedusa frogs. It is a strong, highly selective mu-opioid agonist, the same receptor morphine and fentanyl hit, and in mouse brain-injection studies it was hundreds of times more potent than morphine. It is not approved anywhere for human use. Its main claim to fame is doping: it was caught in dozens of American racehorses in 2012, where it was nicknamed 'frog juice'. This is an opioid, and it should be treated like one.
Key Comparison Insights
- Ziconotide is FDA approved, while Dermorphin remains in research stages.
- Both peptides belong to the Healing category, suggesting similar primary applications.
- Ziconotide has stronger research evidence (FDA Approved) compared to Dermorphin (Animal Studies).
Detailed Comparison
| Attribute | Ziconotide | Dermorphin |
|---|---|---|
| Category | Healing | Healing |
| FDA Status | FDA Approved | Not FDA Approved |
| Clinical Status | Pre I II III IV FDA | Pre I II III IV FDA |
| Mechanism of Action | Ziconotide is a synthetic copy of omega-conotoxin MVIIA (originally SNX-111), a 25-amino-acid peptide with three disulfide bonds found in the venom of the cone snail Conus magus. It blocks N-type voltage-gated calcium channels, which sit on pain-sensing nerves in the spinal cord's dorsal horn. By shutting those channels, it stops the release of pain-signaling neurotransmitters before the message can travel up to the brain. It barely crosses the blood-brain barrier, which is exactly why it has to be infused intrathecally, straight into the cerebrospinal fluid, to reach its targets. | Dermorphin binds the mu-opioid receptor with very high affinity and selectivity. In rat brain binding work it had a Ki of 0.7 nM at mu receptors versus 62 nM at delta and over 5,000 nM at kappa receptors, a selectivity on par with the reference lab mu-agonist DAMGO. It is unusual for a natural peptide because its second amino acid is a D-alanine, which protects it from the enzymes that normally chew up opioid peptides within seconds. Mu activation blocks pain signaling in the spinal cord and brain, and it also drives the classic opioid problems: euphoria, sedation, slowed breathing, constipation, tolerance and dependence. There is no special 'safe' mechanism here. Claims that it is less addictive than morphine are mostly marketing and horse-racing talk, not proven in people. |
| Common Dosing | Limited community data available See research protocols | No safe human dose established Not established |
| Administration | Intrathecal infusion only | Intravenous infusion (human study); intravenous or intramuscular (horse study) |
| Typical Duration | Chronic use via intrathecal pump | Single administrations in research settings |
| Best Time to Take | Morning or as directed | Not applicable |
Possible Side Effects May vary by individual |
|
|
| Research Summary | This one is the opposite of speculative. The FDA approved ziconotide as Prialt on December 28, 2004, and the European Commission followed on February 22, 2005. It is indicated for severe chronic pain in patients who need intrathecal therapy and who cannot tolerate or no longer respond to other options, including intrathecal morphine. Its big advantage over opioids is the apparent absence of tolerance or physical dependence even with long-term use. The big problem is a narrow therapeutic window: dizziness, confusion, memory problems, unsteady gait, and serious psychiatric effects including hallucinations and suicidal thoughts, which is why it carries a black box warning and is contraindicated in people with a history of psychosis. Rapid dosing or aggressive dose escalation makes the adverse effects worse, so it is titrated slowly under specialist care. | Most of the science is animal pharmacology and drug-testing chemistry. A 1990 rat-brain study confirmed dermorphin as a near-specific mu 'super-agonist' and found that, injected into the brains of mice, it was up to 670 times more potent than morphine as a painkiller, with higher doses causing catalepsy. The human data are tiny: a 1986 Brain Research study gave an intravenous infusion of 0.16 mg/kg to healthy volunteers and found a marked, long-lasting rise in the threshold of a spinal pain reflex; naloxone only reversed about half the effect. No modern clinical trials exist. In horses, a 2015 pharmacokinetic study (about 9 mcg/kg IV or IM) found an elimination half-life under an hour, excitation with a raised heart rate after IV dosing, and detection in urine for 48 to 72 hours. The doping story is the reason most people have heard of it: around 30 positive tests turned up in Southern US racing in 2012, including 11 horses tied to nine trainers in Louisiana, which led to suspensions of up to 10 years, and racing labs in Australia, the US and Hong Kong have since built sensitive tests for dermorphin and its synthetic analogs. A 2017 federal indictment charged a Louisiana veterinarian with supplying it to trainers. |
Frequently Asked Questions: Ziconotide vs Dermorphin
What is the difference between Ziconotide and Dermorphin?
Ziconotide is a healing peptide that ziconotide is a real, fda-approved painkiller pulled from the venom of a marine cone snail. it is not an opioid, and unlike morphine, people do not build tolerance to it over time. the catch: it only works delivered directly into the spinal fluid through an implanted pump, and its side effect profile is rough enough that it carries a black box warning. Dermorphin is a healing peptide that dermorphin is a seven-amino-acid opioid peptide (tyr-d-ala-phe-gly-tyr-pro-ser-nh2) first found in the skin of south american phyllomedusa frogs. it is a strong, highly selective mu-opioid agonist, the same receptor morphine and fentanyl hit, and in mouse brain-injection studies it was hundreds of times more potent than morphine. it is not approved anywhere for human use. its main claim to fame is doping: it was caught in dozens of american racehorses in 2012, where it was nicknamed 'frog juice'. this is an opioid, and it should be treated like one. The main differences lie in their mechanisms of action and clinical applications.
Which is better, Ziconotide or Dermorphin?
Neither is universally "better" - the choice depends on your specific goals. Ziconotide is typically used for healing purposes, while Dermorphin is used for healing. Always consult with a healthcare provider to determine which may be appropriate for your situation.
Can Ziconotide and Dermorphin be used together?
Some peptide protocols combine multiple compounds for synergistic effects. However, using Ziconotide and Dermorphin together should only be considered under medical supervision, as both compounds have their own side effect profiles and potential interactions. Research on their combined use may be limited.